(Z)-2,6-dichloro-N-hydroxybenzimidoyl chloride | 6579-27-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-2,6-dichloro-N-hydroxybenzimidoyl chloride
• 英文别名: 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride；(1Z)-2,6-dichloro-N-hydroxybenzenecarboximidoyl chloride
• CAS: 6579-27-7
• 化学式: C₇H₄Cl₃NO
• 分子量: 224.474
• InChiKey: LXWQVTNZUIURFE-XFFZJAGNSA-N

物化性质

• 熔点：
  85 °C
• 沸点：
  349.2±52.0 °C(Predicted)
• 密度：
  1.53

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 海关编码：
  2925290090

SDS

Name:	2 6-Dichloro-n-hydroxybenzenecarboximidoyl chloride Material Safety Data Sheet
Synonym:	None know
CAS:	6579-27-7

Section 1 - Chemical Product MSDS Name:2 6-Dichloro-n-hydroxybenzenecarboximidoyl chloride Material Safety Data Sheet
Synonym:None know

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6579-27-7	2,6-Dichloro-n-hydroxybenzenecarboximi	TECH	unlisted

Hazard Symbols: C
Risk Phrases: 20/21/22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed. Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Harmful if absorbed through the skin. Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Harmful if inhaled. Causes chemical burns to the respiratory tract.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6579-27-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 84 - 87 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H4Cl3NO
Molecular Weight: 224.48

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Water, strong oxidizing agents, reducing agents, strong bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, hydrogen cyanide, carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6579-27-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,6-Dichloro-n-hydroxybenzenecarboximidoyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 34 Causes burns.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6579-27-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6579-27-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6579-27-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (Z)-2,6-dichloro-N-hydroxybenzimidoyl chloride 在 三乙胺 、 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-thione 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 以97%的产率得到2,6-二氯异硫氰酸苯酯
  参考文献：
  名称：

  Collins, David J.; Hughes, Timothy C.; Johnson, Wynona M., Australian Journal of Chemistry, 2000, vol. 53, # 2, p. 137 - 141

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-2,6-二氯苯甲醛肟 在 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (Z)-2,6-dichloro-N-hydroxybenzimidoyl chloride
  参考文献：
  名称：

  设计为新型杀菌剂的呋喃喃衍生物的合成及抗真菌活性。

  摘要：

  设计并合成了呋喃喃衍生物3-11作为潜在的杀菌剂。通过原位由N-羟基亚氨酰氯2生成的相应的腈氧化物的二聚作用，制备对称取代的呋喃喃衍生物3a-j。关键中间体醛4的进一步官能团修饰生成了呋喃喃衍生物5-11。在250 ppm的广谱植物真菌中观察到了呋喃喃衍生物3-11的杀真菌活性。

  DOI：

  10.1271/bbb.62.1693

文献信息

• [EN] COMPOUNDS AND METHODS FOR MODULATING FXR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR MODULER LE FXR
  申请人：LILLY CO ELI

  公开号：WO2009012125A1

  公开（公告）日：2009-01-22

  Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.

  公式(I)的化合物：其中变量如本文所述定义，其药物组合物及其用途被披露为用于治疗血脂异常以及与血脂异常相关的疾病。
• [EN] HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS<br/>[FR] MODULATEURS DU RÉCEPTEUR HORMONAL POUR LE TRAITEMENT D'ÉTATS ET DE TROUBLES MÉTABOLIQUES
  申请人：ARDELYX INC

  公开号：WO2018039386A1

  公开（公告）日：2018-03-01

  The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

  这项发明涉及FXR的激活剂，可用于治疗自身免疫性疾病、肝病、肠道疾病、肾脏疾病、癌症以及FXR在其中发挥作用的其他疾病，其化学式为(I)：(I)，其中L1、A、X1、X2、R1、R2和R3如本文所述。
• Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses
  申请人：Singh Rajinder

  公开号：US20060247287A1

  公开（公告）日：2006-11-02

  The present invention relates to prodrugs and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及取代二苯基、二杂环基和混合苯基杂环基取代的五元杂环化合物的前药，包含该化合物的组合物以及利用这些化合物和组合物来抑制HCV复制和/或增殖，作为治疗和/或预防人类和动物HCV感染的治疗方法。
• FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF
  申请人：Guangzhou Henovcom Bioscience Co. Ltd.

  公开号：EP3401315A1

  公开（公告）日：2018-11-14

  The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

  本公开揭示了一种FXR受体调节剂及其制备和使用，涉及药物化学技术领域。本公开提供了一种具有结构式I或其药用可接受盐、立体异构体、溶剂合物或前药的FXR受体调节剂，可与FXR受体（即NR1H4）结合，并作为FXR激动剂或部分激动剂用于预防和治疗由FXR介导的疾病，如慢性肝内或肝外胆汁淤积、慢性胆汁淤积或急性肝内胆汁淤积引起的肝纤维化、慢性乙型肝炎、胆结石、肝癌、结肠癌或肠道炎症性疾病等。具体而言，对于某些化合物，它们的FXR激动剂活性的EC50值低于100nM，表现出优异的FXR激动剂活性，并有望为由FXR介导的疾病在临床治疗中提供新的药物选择。
• Efficient Access to Isoxazoles from Alkenes
  作者：Ashton Hamme II、Jianping Xu

  DOI：10.1055/s-2008-1042906

  日期：2008.4

  The direct regioselective synthesis of 3,5-disubstituted isoxazoles was achieved in one reaction vessel through a sequence of reactions involving the net bromination of an electron-deficient alkene, in situ generation of a nitrile oxide, 1,3-dipolar cycloaddition, and loss of HBr from an intermediate 5,5-disubstituted bromoisoxazoline. This one-pot process enables the synthesis of 3,5-disubstituted

  3,5-二取代异恶唑的直接区域选择性合成是在一个反应​​容器中通过一系列反应实现的，包括缺电子烯烃的净溴化、腈氧化物的原位生成、1,3-偶极环加成和损失HBr 来自中间体 5,5-二取代溴异恶唑啉。这种一锅法可以直接从缺电子烯烃合成 3,5-二取代异恶唑，从而消除 1,1-二取代溴烯烃炔替代物的分离。